Health Stocks in Motion

Updated from 2:26 p.m. EDT

Shares of Cardiac Science ( DFIB) were among the worst-performing health and pharmaceutical stocks Friday after the company posted second-quarter results that missed expectations and warned that third-quarter results would fall below expectations as well.

The maker of defibrillators posted a loss of 7 cents a share on sales of $17.5 million. Analysts polled by Thomson First Call had expected it to post a loss of 4 cents a share on sales of $17.5 million. Looking ahead, it expects to report a third-quarter loss of 4 cents to 6 cents a share, wider than the loss of 2 cents a share analysts had been expecting. Sales, meanwhile, are now expected to be $16.5 million to $18.5 million. Analysts were looking for $18.8 million. Shares of Cardiac Science traded down 85 cents, or 29.6%, to $2.02.

Viasys Healthcare ( VAS) fell after it reported weaker-than-expected second-quarter earnings. Excluding items, the health care technology company posted earnings of 13 cents a share on sales of $95.4 million. Analysts had expected it to earn 22 cents a share on sales of $104.7 million. Looking ahead, the company said that first- and second-quarter results lead it to believe that full-year earnings and sales will be equal to results from 2003. Shares of Viasys Healthcare traded down $3.48, or 18.7%, to $15.15.

Shares of Gilead Sciences ( GILD) rose after the company reported blowout second-quarter earnings and sales. The biotech company posted earnings of 49 cents a share on sales of $319.7 million. Analysts had predicted that it would earn 36 cents a share on sales of $285.8 million. A year ago it earned 46 cents a share on sales of $238.9 million. Shares of Gilead Sciences traded up $5.14, or 8.6%, to $64.64.

Staar Surgical ( STAA) fell after it reported weaker-than-expected second-quarter earnings and sales and warned that full-year results would fall short of expectations. The medical device maker posted a second-quarter loss of 18 cents a share on sales of $12 million. Analysts had expected a smaller loss of 7 cents a share on sales of $13.8 million. Looking ahead, Staar expects a full-year loss of 52 cents to 55 cents a share, substantially higher than the loss of 20 cents that analysts were expecting. Shares of Staar Surgical traded down 72 cents, or 12%, to $5.29.

Shares of Cytyc ( CYTC) rose after the company turned in better-than-expected second-quarter earnings. The medical device company earned 19 cents a share on sales of $99.5 million. Analysts had expected it to earn 18 cents a share on sales of $98.7 million. Strong sales of NovaSure, which is used to treat excessive menstrual bleeding, fueled the second-quarter results. Shares of Cytyc traded up $2.31, or 10.6%, to $24.10.

Other health care volume movers included Pfizer ( PFE), up 3 cents to $31.96; Bristol-Myers ( BMY), up 33 cents to $22.90; Amgen ( AMGN), down 1 cent to $56.99; Boston Scientific ( BSX), up 99 cents to $38.26; Schering-Plough ( SGP), down 7 cents to $19.46; and Genentech ( DNA), up 55 cents to $48.68.

More from Stocks

Tyson Foods CEO: We Aren't Done Making Deals

Tyson Foods CEO: We Aren't Done Making Deals

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

Warren Buffett at Age 87 Still Does One Amazing Thing That Drives Success

Warren Buffett at Age 87 Still Does One Amazing Thing That Drives Success

Amazon, Nvidia, Micron and 10 Other Stocks to Own in June

Amazon, Nvidia, Micron and 10 Other Stocks to Own in June

3 Great Stocks for Retirees to Own

3 Great Stocks for Retirees to Own